Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Thyroid Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


15 drugs have received FDA approval for Thyroid Cancer . Axicabtagene Ciloleucel, COPANLISIB HYDROCHLORIDE, Cabozantinib-S-Malate, Dabrafenib, Doxorubicin Hydrochloride, Duvelisib, Idelalisib, Lenvatinib Mesylate, Obinutuzumab, Recombinant Interferon Alfa-2b, Rituximab, Sorafenib Tosylate, Tisagenlecleucel, Trametinib and Vandetanib
219 drugs have a clinical trial registered for Thyroid Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 943 clinical trials for Thyroid Cancer,
595 of which have one or more drug interventions,
348 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 138 Cell Line Models for Thyroid Cancer.

Source: COSMIC
(see details)

Chemistry


There are 407 Compounds which have been tested in Thyroid Cancer , 324 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Thyroid Cancer:
Adenocarcinoma, Follicular
Lymphoma, Follicular
Parathyroid Neoplasms
Thyroid Cancer, Papillary
Thyroid Carcinoma, Anaplastic
Thyroid Neoplasms

The following terms have been mapped from cancer.gov to Thyroid Cancer:
Anaplastic thyroid cancer in patients whose disease is locally advanced or has metastasized (spread to other parts of the body) and who cannot receive local treatment. It is used with dabrafenib
Anaplastic thyroid cancer in patients whose disease is locally advanced or has metastasized (spread to other parts of the body) and who cannot receive local treatment. It is used with trametinib
B-cell non-Hodgkin lymphoma (NHL) that is CD20 positive.It is used alone in patients with follicular lymphoma or low-grade lymphoma that has relapsed or is refractory (doesn??????t respond to treatment)
DLBCL in patients who had follicular lymphoma
DLBCL in patients who had follicular lymphoma.
Follicular lymphoma that is aggressive. It is used with combination chemotherapy in adults
Follicular lymphoma that has relapsed or is refractory. It is used in adults who have received at least two other systemic therapies
Follicular lymphoma that has relapsed. It is used in adults who have received at least two other systemic treatments
Follicular lymphoma. It is used in adults with follicular lymphoma that:Has relapsed or is refractory (does not respond to treatment)
Follicular lymphoma. It is used:With bendamustine hydrochloride and then by itself to treat follicular lymphoma that relapsed after treatment with rituximab or did not respond to the treatment
Medullary thyroid cancer that cannot be removed by surgery and is locally advanced or has metastasized (spread to other parts of the body)
Medullary thyroid cancer that is progressive and has metastasized (spread to other parts of the body). This use is approved for the Cometriq brand of cabozantinib-s-malate
Non-Hodgkin lymphoma (NHL) that has recurred (come back). It is used in patients who have already received at least two systemic treatments. It is used in the following types of NHL--Follicular B-cell non-Hodgkin lymphoma
Thyroid cancer
Thyroid cancer in certain patients with progressive, recurrent, or metastatic disease that does not respond to treatment with radioactive iodine
With chemotherapy as first-line treatment in adults with stage II bulky, stage III, or stage IV follicular lymphoma. Patients who have at least a partial remission are then treated with obinutuzumab by itself